119.17
-1.54
(-1.28%)
At close: April 9 at 6:58:23 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 9 | 9 |
| Avg. Estimate | 8.87B | 9.62B | 39.74B | 43.47B |
| Low Estimate | 8.63B | 9.5B | 38.59B | 41.73B |
| High Estimate | 9.13B | 9.77B | 41.24B | 46.12B |
| Year Ago Sales | 7.93B | 8.39B | 35.77B | 39.74B |
| Sales Growth (year/est) | 11.81% | 14.70% | 11.10% | 9.39% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0HQP.L | -- | -- | -- | -- |
| S&P 500 | 6.52% | 6.29% | 9.55% | 14.25% |
Upgrades & Downgrades
| Maintains | Morgan Stanley: Overweight to Overweight | 2/19/2025 |
| Maintains | Keefe, Bruyette & Woods: Market Perform to Market Perform | 2/14/2025 |
| Downgrade | Raymond James: Strong Buy to Outperform | 1/24/2025 |
| Upgrade | Morgan Stanley: Equal-Weight to Overweight | 1/15/2025 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 1/13/2025 |
| Upgrade | Jefferies: Hold to Buy | 1/2/2025 |